Current location: slot game xbox > hit it rich casino slots game > 80 jili > main body

80 jili

2025-01-13 2025 European Cup 80 jili News
80 jili
80 jili AI-Powered Google Search Optimization: A Beginner’s Guide to NytroSEO

Commercial Turf Equipment Set For Strong Growth Reaching $8.12 Billion At A CAGR Of 5.6% By 2028

NoneWomen more likely to need walking aids but less likely to use them – study

Fianna Fail and Fine Gael eye independent TDs as option to secure Dail majority

Forex reserves drop by record $18 billion in a weekNEW YORK--(BUSINESS WIRE)--Dec 12, 2024-- Goldman Sachs Asset Management, the investment adviser for the Goldman Sachs Bloomberg Clean Energy Equity ETF, Goldman Sachs North American Pipelines & Power Equity ETF and Goldman Sachs Future Real Estate and Infrastructure Equity ETF (each, a “Fund” and collectively, the “Funds”), announced today that the Funds’ Board of Trustees, at the recommendation of Goldman Sachs Asset Management, has approved a plan of liquidation for each Fund (collectively, the “Plans”). Under the Plans, which are effective today, the Funds will begin the process of liquidating portfolio assets and unwinding their affairs in an orderly fashion over time. The Plans are not subject to shareholder approval. Shareholders of the Funds may sell their shares on the Fund’s listing exchange, Cboe BZX Exchange, Inc. (“Cboe”) for the Goldman Sachs Bloomberg Clean Energy Equity ETF and Goldman Sachs North American Pipelines & Power Equity ETF or NYSE Arca, Inc. (“NYSE Arca”) for the Goldman Sachs Future Real Estate and Infrastructure Equity ETF until market close on January 10, 2025, and may incur transaction fees from their broker-dealer. The Funds’ shares will no longer trade on Cboe or NYSE Arca, as applicable, after market close on January 10, 2025, and the shares will subsequently be de-listed. Shareholders who continue to hold shares of a Fund on the Funds’ liquidation date, which is expected to be on or about January 17, 2025, will receive a liquidating distribution of cash in the cash portion of their brokerage accounts equal to the amount of the net asset value of their shares. For tax purposes, shareholders will generally recognize a capital gain or loss equal to the amount received for their shares over their adjusted basis in such shares. The Funds will stop accepting creation orders from Authorized Participants on January 10, 2025. About Goldman Sachs Asset Management Goldman Sachs Asset Management is the primary investing area within Goldman Sachs (NYSE: GS), delivering investment and advisory services across public and private markets for the world’s leading institutions, financial advisors, and individuals. The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets. Goldman Sachs Asset Management is a leading investor across fixed income, liquidity, equity, alternatives, and multi-asset solutions. Goldman Sachs oversees approximately $3.1 trillion in assets under supervision as of September 30, 2024. Follow us on LinkedIn . The Goldman Sachs Bloomberg Clean Energy Equity ETF (the “Fund”) seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the Bloomberg Goldman Sachs Global Clean Energy Index (the “Index”), which delivers exposure to companies that are expected to have a significant impact on energy decarbonization through their exposure to clean energy. The Fund’s investments are subject to market risk , which means that the value of the securities in which it invests may go up or down in response to the prospects of individual companies, particular sectors or governments and/or general economic conditions. Foreign and emerging markets investments may be more volatile and less liquid than investments in U.S. securities and are subject to the risks of currency fluctuations and adverse social, economic or political developments. Because the Fund may have significant investments in the clean energy sector , the Fund is subject to risk of loss as a result of adverse economic, business or other developments affecting industries within that sector. The securities of mid- and small-capitalization companies involve greater risks than those associated with larger, more established companies and may be subject to more abrupt or erratic price movements. The Fund is not actively managed, and therefore the Fund will not generally dispose of a security unless the security is removed from the Index. The Index calculation methodology may rely on information based on assumptions and estimates and neither the Fund, the index provider nor the investment adviser can guarantee the accuracy of the methodology’s valuation of securities or the availability or timeliness of the production of the Index. Performance may vary substantially from the performance of the Index as a result of transaction costs, expenses and other factors. The Goldman Sachs North American Pipelines & Power Equity ETF (the “Fund”) seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the Solactive Energy Infrastructure Enhanced Index (the “Index”), which is designed to deliver exposure to equity securities of U.S. and Canadian listed companies including companies structured as master limited partnerships (“MLPs”), operating in the pipelines and power universe. The Fund’s investments are subject to market risk , which means that the value of the securities in which it invests may go up or down in response to the prospects of individual companies, particular sectors or governments and/or general economic conditions. Foreign investments may be more volatile and less liquid than investments in U.S. securities and are subject to the risks of currency fluctuations and adverse economic, social or political developments, including sanctions, counter-sanctions and other retaliatory actions. Investments in MLPs are subject to certain additional risks, including risks related to limited control and limited rights to vote on matters affecting MLPs, potential conflicts of interest, cash flow risks, dilution risks, limited liquidity , risks related to the general partner’s right to force sales at undesirable times or prices, interest rate sensitivity and for MLPs with smaller capitalizations, lower trading volume and abrupt or erratic price movements. MLPs are also subject to risks relating to their complex tax structure , including the risk that an MLP could lose its tax status as a partnership, resulting in a reduction in the value of the Fund’s investment in the MLP and lower income to the Fund. MLPs are also subject to the risk that to the extent that a distribution received from an MLP is treated as a return of capital, the Fund’s adjusted tax basis in the MLP interests may be reduced, which may increase the Fund’s tax liability upon the sale of the MLP interests or upon subsequent distributions in respect of such interests. Many MLPs in which the Fund invests operate facilities within the energy sector and are also subject to risks affecting that sector . Because the Index currently concentrates its investments in the energy sector , the Fund is subject to greater risk of loss as a result of adverse economic, business or other developments affecting that industry or group of industries. The Fund is not actively managed , and therefore the Fund will not generally dispose of a security unless the security is removed from the Index. The Index calculation methodology may rely on information based on assumptions and estimates and neither the Fund, the index provider nor the investment adviser can guarantee the accuracy of the methodology’s valuation of securities or the availability or timeliness of the production of the Index. Performance may vary substantially from the performance of the Index as a result of transaction costs, expenses and other factors. The Fund is non-diversified and may invest a larger percentage of its assets in fewer issuers than “diversified” funds. Accordingly, the Fund may be more susceptible to adverse developments affecting any single issuer held in its portfolio and to greater losses resulting from these developments. The Goldman Sachs Future Real Estate and Infrastructure Equity ETF (the “Fund”) seeks long-term growth of capital. The Fund is an actively managed exchange-traded fund. The Fund pursues its investment objective by primarily investing in U.S. and non-U.S. real estate and infrastructure companies that the Investment Adviser believes are aligned with key themes associated with secular growth drivers for real estate and infrastructure assets. The Fund’s investments are subject to market risk , which means that the value of the securities in which it invests may go up or down in response to the prospects of individual companies, particular sectors or governments and/or general economic conditions. The Fund’s thematic investment strategy limits the universe of investment opportunities available to the Fund and may affect the Fund’s performance relative to similar funds that do not seek to invest in companies exposed to such themes. The Fund relies on the Investment Adviser for the identification of companies the Investment Adviser believes are aligned with key themes associated with secular growth drivers for real estate and infrastructure assets, and there is no guarantee that the Investment Adviser’s views will reflect the beliefs or values of any particular investor or that real estate and infrastructure companies in which the Fund invests will benefit from their associations with secular growth drivers for real estate and infrastructure assets. Different investment styles (e.g., “growth” and “value”) tend to shift in and out of favor, and at times the Fund may underperform other funds that invest in similar asset classes. Because the Fund concentrates its investments in certain specific industries, the Fund is subject to greater risk of loss as a result of adverse economic, business or other developments affecting those industries than if its investments were more diversified across different industries . Stock prices of real estate and infrastructure companies in particular may be especially volatile. Investing in Real Estate Investment Trusts (“REITs”) involves certain unique risks in addition to those risks associated with investing in the real estate industry in general. REITs whose underlying properties are focused in a particular industry or geographic region are also subject to risks affecting such industries and regions. The securities of REITs involve greater risks than those associated with larger, more established companies and may be subject to more abrupt or erratic price movements because of interest rate changes, economic conditions and other factors. Foreign and emerging markets investments may be more volatile and less liquid than investments in U.S. securities and are subject to the risks of currency fluctuations and adverse economic, social or political developments, including sanctions, counter-sanctions and other retaliatory actions. Such securities are also subject to foreign custody risk. The securities of mid- and small-capitalization companies involve greater risks than those associated with larger, more established companies and may be subject to more abrupt or erratic price movements. The Fund is “ non-diversified ” and may invest a larger percentage of its assets in fewer issuers than “diversified” funds. In addition, the Fund may invest in a relatively small number of issuers . Accordingly, the Fund may be more susceptible to adverse developments affecting any single issuer held in its portfolio and to greater losses resulting from these developments. Fund shares are not individually redeemable and are issued and redeemed by a Fund at their net asset value (“NAV”) only in large, specified blocks of shares called creation units. Shares otherwise can be bought and sold only through exchange trading at market price (not NAV). Shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns. A summary prospectus, if available, or a Prospectus for each Fund containing more information may be obtained from your authorized dealer or from Goldman Sachs & Co. LLC by calling 1-800-621-2550. Please consider a Fund's objectives, risks, and charges and expenses, and read the summary prospectus, if available, and the Prospectus carefully before investing. The summary prospectus, if available, and the Prospectus contains this and other information about the Funds. The Investment Company Act of 1940 (the “Act”) imposes certain limits on investment companies purchasing or acquiring any security issued by another registered investment company. For these purposes the definition of “investment company” includes funds that are unregistered because they are excepted from the definition of investment company by sections 3(c)(1) and 3(c)(7) of the Act. You should consult your legal counsel for more information. Goldman Sachs does not provide accounting, tax or legal advice. © 2024 Goldman Sachs All rights reserved NOT FDIC INSURED. MAY LOSE VALUE. NO BANK GUARANTEE. NOT INSURED BY ANY GOVERNMENT AGENCY. ALPS Control: GST: 2818 Compliance Code: 402923-OTU-2167293 Date of first use: 12/12/2024 View source version on businesswire.com : https://www.businesswire.com/news/home/20241212407058/en/ CONTACT: Media: Victoria Zarella Tel: 212-902-5400 KEYWORD: NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: ASSET MANAGEMENT PROFESSIONAL SERVICES FINANCE SOURCE: Goldman Sachs Asset Management Copyright Business Wire 2024. PUB: 12/12/2024 05:12 PM/DISC: 12/12/2024 05:10 PM http://www.businesswire.com/news/home/20241212407058/enPalantir Technologies ( PLTR -3.72% ) was one of the best-performing stocks of 2024. A strong start to the year for the artificial intelligence (AI)-powered enterprise software company went into overdrive in September. A strong earnings report and its addition to the S&P 500 that month stoked a ton of buying for the stock. The market has continued to push the stock higher, bringing the company's market cap above $187 billion, as of this writing. Palantir's financial results have been spectacular. But many analysts think the stock has gotten ahead of itself. Just three out of 22 Wall Street analysts covering the stock give it an overweight or buy rating. Moreover, none of them have a 12-month price target higher than its current stock price. Indeed, Palantir's stock valuation makes it tough to buy now . But investors looking to add some AI stocks to their portfolio have plenty of other options. And two other companies look far more attractive than the richly valued Palantir. In fact, I predict both will be worth more than Palantir by the end of 2025, as a result of strong relative price performance to 2024's big winner. There are two big shifts going on that increase the demand for Palo Alto Networks ' ( PANW -1.23% ) cybersecurity services. More and more enterprises are shifting from on-premise storage and compute for their data and software needs to cloud computing . As they migrate to the cloud or adopt a hybrid approach, they increase the number of potential attack points for cyber criminals. Additionally, most workplaces have adopted a hybrid approach to working in the office versus working from home. Again, this opens more potential security vulnerabilities. Palo Alto offers security solutions across clients' networks (firewalls) in both hardware and software formats. It also offers solutions for the cloud and endpoint security, ensuring only authorized devices gain access to sensitive network data. Many cybersecurity providers rely on machine learning artificial intelligence to help detect cybersecurity threats early and close vulnerabilities. One of the biggest challenges for building an effective system based on machine learning is accessing valuable data. As a leader in the space, Palo Alto has a considerable data advantage over the competition. As such, its AI efforts pay off handsomely, as they work better than competitors. What's more, Palo Alto's capabilities make it more attractive to new customers, creating a virtuous cycle, whereby it gains access to more valuable data than its competitors. On top of that, it's important to consider the switching costs for existing customers. Few security analysts are going to risk their job to save a few bucks for their company on a competing product. Just the opposite, they're more likely to go back to Palo Alto Networks when their needs expand. Palo Alto has been expanding its offerings through bolt-on acquisitions over time, and it's seen considerable success cross-selling customers on new products. As the company shifts to more software-based solutions and increases its cross-selling to customers, its gross margin should continue to move higher over time. As such, investors should see profits climb considerably faster than revenue for the foreseeable future. Palo Alto's shares currently trade for an enterprise-value -to-revenue ratio of 14.6. That's a fair price to pay. And if it can maintain that multiple through fiscal 2025, the stock should climb around 14% based on analysts' estimates. With a market capitalization of $124 billion, as of this writing, that would put its value at about $142 billion at the end of 2025. That would require Palantir stock to drop about 24% from today's price to fall below Palo Alto's potential market cap. 2. Micron Technology When it comes to semiconductors , just a few companies get most of the attention. Most people know the big GPU makers like Nvidia . But one company making critical components of AI chips like Nvidia's is Micron Technology ( MU -1.32% ) . Micron supplies memory chips, including standard DRAM and NAND chips found in PCs and smartphones. It also makes chips called high-bandwidth memory (HBM), which manufacturers like Nvidia incorporate into their high-end GPUs. As a result, Micron has been a big beneficiary of the growing spending and development in artificial intelligence. Micron's data center revenue grew more than 400% year over year in its first quarter, which ended in November. The segment, led by its HBM chips, now accounts for more than 50% of Micron's total sales. Management is extremely optimistic about the potential for AI to transform its business. It sees the HBM market growing from $16 billion in 2024 to $100 billion by 2030. Considering just three companies, including Micron, make HBM chips, Micron is sure to see its fair share of that growth. The strength of the data center business can offset short-term weakness in the consumer segment. Management lowered its forecast for the second quarter due to customer inventory reductions from PC and smartphone suppliers. The consumer segment slowdown points to the biggest risk of investing in Micron: cyclicality . Micron manufactures its own chips in-house. That requires significant capital expenditures up front, but results in relatively stable growth in cost of goods as it expands production capacity. Micron's chips are practically interchangeable with its competitors', which makes its pricing commodity-like. In other words, when there's strong demand for Micron's chips, it sees more orders and better pricing while its cost of production remains relatively flat. When demand falls, it receives less revenue, but it's still paying the same amount, potentially resulting in negative returns on invested capital . It seems likely Micron will continue to see very high demand for its HBM chips in 2025, as several big tech companies have laid out plans to substantially grow their data center spending. That should more than offset weakness in the consumer segment, and analysts expect 39.6% revenue growth for the year. At an enterprise-value-to-revenue ratio of 3.7 as of this writing, shares look undervalued, despite the cyclicality risk. If shares expand their multiple to 4 over the next year, and analysts' estimates pan out, Micron would see its stock climb about 50% next year. That would put its market cap around $150 billion. A 20% drop in Palantir shares over the next year would put it below that number. Regardless of whether Micron or Palo Alto Networks end up being worth more than Palantir by the end of 2025, both look far more attractive than the highflier at today's prices.

Social media mourns death of Jimmy CarterOur community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info A doctor has warned that the mysteriously named Disease X could become the next huge pandemic, adding that the world is not prepared for a sudden boom in cases. Disease X - which is the name given to a as-yet-uknown infection - is among 11 diseases which have been described as dangerous by doctors , reports the Mirror. Measles, cholera, scabies, bird flu, and even another Covid outbreak were also named in the list of scientists' most feared infections for 2025. The World Health Organization (WHO) had previously classed the unknown pathogens as Disease X, and it was included in its own priority list of diseases that needed researched urgently. Recently, the disease killed at least 31 people - mainly children - in the Panzi region of the Democratic Republic of Congo (DRC). The WHO revealed that there were more than 400 recorded cases of an undiagnosed disease in the DRC between October 24 and December 5. The most common symptoms included fever, headache, body aches, and a bad cough. However, the most severe cases were linked to severe malnutrition, they added. Disease X is one of the infections that's is likely to lead to severe outbreaks, and potentially a pandemic, according to Dr Michael Head; Senior Research Fellow in Global Health at the University of Southampton. If an outbreak was to happen immediately, the world is likely to be severely unprepared, similar to the global shock of coronavirus. Disease X does not refer to one infection but a name given to any disease that has not yet been identified. However, the idea of an unknown virus or bacterial infection is very real, and scientists have urged governments to be prepared for anything Mother Nature might throw at us. "Disease X is the name given to an as-yet-unknown bug, that has the potential to cause large outbreaks or even a pandemic," Dr Head told the Mirror. "This bug would have the potential to spread quickly and have a high mortality rate; for example like COVID-19. "The world was poorly prepared for the most recent pandemic, and though we have significant advances in technology, such as the use of mRNA platforms for vaccines and other medicines, we would likely fall short again should Disease X emerge tomorrow." Dengue fever is the world's most commonly transmitted virus, spread by mosquitoes. Tens of millions of cases are contracted per year, and up to 25,000 people die annually. Commonly found in South America and Southeast Asia, more cases are popping up in southern Europe - mainly due to climate change. France, Italy and Spain are most likely to see outbreaks of dengue - which is also referred to as the 'bone breaker' disease. The mosquito that carries the virus is eventually expected to gain a foothold in the UK. However, it's still unknown when that might be. Medicine professor at the University of East Anglia, Paul Hunter, expected to see more cases of dengue fever in 2025 - specifically in southern Europe. This year, there was only one confirmed case of chikungunya in Europe, although it could potentially be on the rise in the coming year, warned Professor Hunter. It's another mosquito-driven viral infection, and is similar to the mayaro virus and the ross river virus. Nearly all cases of the virus are found in South America; particularly in Brazil, which had more than 400,000 between August and October in 2024. Yet, as European climates are becoming more favourable for mosquitoes, and scientists fear chikungunya could be on the rise. Professor Hunter said: "I think we will likely see more mosquito-borne diseases in southern Europe; mainly dengue but also probably chikungunya. I also worry about West Nile fever." The West Nile virus is not often noticed in about 80% of human patients. However, for those remaining 20%, it can lead to deadly West Nile fever. The virus is transmitted by mosquito bite, although it could also be spread by blood transfusions and organ transplants. It's still to be reported by local transmission in the UK, but there have been cases of travellers returning with the infection. Human infections have been reported in Spain, France, Italy, Greece, and Germany since the start of November 2024. At its worst, West Nile fever can develop into West Nile neuroinvasive disease (WNND). WNND describes when the nervous system is directly affected by the virus, and it can include developing meningitis, encephalitis, and acute flaccid myelitis. Measles is an extremely serious airborne infection that mainly affects young children. Over 107,000 people died from measles globally in 2023, a majority of whom were under fives years old. It's spread by coughing or sneezing, moving in air droplets, and can live in the air or on surfaces for up to two hours. That makes it highly infectious, and infects about 90% of all unvaccinated people within close contact. Measles has been on the rise in the western world over the past few years, largely driven by a fall in vaccination rates. The proportion of kids receiving their first dose of the measles vaccine in 2019 was 86%. But that fell to 83% in 2023. Dr Head said: "Measles is vaccine-preventable. With two doses of the MMR vaccine, that stops measles in its tracks. With a high uptake, we could literally eradicate it from the planet, like smallpox. A lower uptake, partly due to too much covid interrupting health service delivery in the pandemic, means children in the UK and globally are being affected. It is a nasty infection in unvaccinated children, and it can and does kill." Coronavirus has been around since the beginning of the pandemic, and has never left. It's also still mutating and changing, with new strains harbouring the potential to become more infections and potentially vaccine-resistant. In October 2024, the UK Health Security Agency (UKHSA) confirmed a new variant appeared to be more infectious than previous strains. The XEC variant, which combined strains of KS.1.1 and KP.3.3 suddenly sparked a big rise in Covid cases across the country. Admission rates for people testing positive for Covid rose from 3.7 per 100,000 to 4.5 per 100,000 in just one week. Dr Head said: "The vaccines, along with use of medicines and diagnostics etc., have massively blunted the public health impact of COVID -19. But, it’s still here, very much hasn’t gone away, and will continue to pose a problem to health services and populations everywhere around the world. Do get vaccinated if another dose if offered to you!" The WHO has warned that cholera is a global public health threat. Caused by consuming food or water contaminated with Vibrio cholerae bacteria, it's a severe diarrhoeal disease. In the most extreme cases, the infection can develop extremely fast, leading to death within a few hours if not treated. Up to 143,000 people die from cholera each year worldwide. There have been seven cholera pandemics since in the 19th century, with the most recent in 1961 largely affecting south Asia. But forced migration, sparked by climate change, could mean that 2025 sees another big surge in cholera cases, warned Professor Hunter. Still, cholera cases are incredibly rare in Europe, and most confirmed cases are found in Africa and Asia. In 2022, for example, 29 cases were reported by nine EU countries; all of which included a history of travel to a cholera hotspot. Avian flu, or bird flu as it's known, is widely accepted as the most likely known cause of the next pandemic. It's a form of flu virus that commonly spreads among birds, but has been known to move across to humans. The virus isn't easily passed to humans, although it can mutate rapidly, leaving scientists fearing a mass outbreak. As it stands, almost all cases of H5N1 - the most common bird flu strain in humans - have been reported in those that work closely with animals. "A permanent member of any ‘possible infectious disease threat’ list, avian influenza evolves its shape and style a little like the Covid variants, and has the potential to cause a pandemic," said Dr Head. "We haven’t yet seen widespread human-to-human transmission - but we could do." Bird flu is spread to humans by touching infected animals, their droppings or bedding, or by preparing infected poultry for cooking. There isn't a seasonal bird flu vaccine, but a universal jab to protect against all types of flu, including avian flu, would be the "holy grail", added Dr Head. Antibiotic-resistant infections continue to rise in the UK, the UKHSA has warned. With the WHO stating that antimicrobial resistance is a top global health threat. Antimicrobials are medicines commonly used to treat infectious diseases, including antibiotics, antivirals and antifungals. Scientists have warned that these infections are taking increasingly longer to react to the medications, as they're evolving and developing to protect against them. Individuals who catch a bacterial infection that's resistant to antibiotics are more likely to die within 30 days, according to the UKHSA. Professor Hunter added that antimicrobial-resistant bacteria posed a "significant concern" going into 2025. E.coli is by far the most common type of antibiotic-resistant bacteria in the UK, which commonly causes diarrhoea, vomiting, and urinary tract infections. By the middle of 2024, the UK reported more than 600 cases of the bacteria, which was markedly more than seen in previous years. UKHSA Chief Executive, Professor Dame Jenny Harries, said in November: "Increasingly the first antibiotics that patients receive aren’t effective at tackling their infections. That’s not just an inconvenience – it means they are at greater risk of developing a severe infection and sepsis. Our declining ability to treat and prevent infections is having an increasing impact, particularly on our poorest communities. "Only take antibiotics if you have been told to do so by a healthcare professional. Do not save some for later or share them with friends and family. This isn’t just for your own health - it’s about protecting everyone in our communities and future generations." Pertussis, or whooping cough, is a bacterial infection that affects the lungs, and can be deadly if left untreated. It often affects young children and babies, but any can develop symptoms if they become infected. The infection is named after the characteristic 'whoop' sound made by infected young babies between deep breaths. Yet, not all babies make the noise, which means it can go untreated for some time. The UK is in the middle of a major whooping cough outbreak, and annual confirmed cases topped 10,000 in August. The second quarter of the year saw higher confirmed cases than any of the quarters in 2012, which was the last major outbreak year. Professor Hunter said it remained unclear whether there would be more cases of whooping cough in 2025 than 2024, but it remained a "big concern". At least 10 infants have died in the UK since the start of the current outbreak, which dates back to November 2023. UKHSA's Director of Immunisation, Dr Mary Ramsay, said earlier this year: "Vaccination is the best defence against whooping cough and it is vital that pregnant women and young infants receive their vaccines at the right time. Pregnant women are offered a whooping cough vaccine in every pregnancy, ideally between 20 and 32 weeks. "This passes protection to their baby in the womb so that they are protected from birth in the first months of their life when they are most vulnerable and before they can receive their own vaccines." Recently, doctors have urged Brits to avoid ignoring the signs of scabies infestation, after a spike in cases. The condition is caused by tiny mites burrowing into the skin to lay their eggs, sparking a really unpleasant itchy rash. Scabies doesn't cause death in many people, but it can really affect your quality of life, according to Dr Head. It's particularly common in the UK, and is mainly seen in institutional settings, including schools, care homes, and prisons. The number of confirmed scabies cases in England increased by 58% in the first half of 2024, compared with 2023. GP diagnoses were also well above the five-year average, with the north of England seeing the largest proportion of cases. "The mites burrow under the skin, causing an immune response that triggers inflammation and itching," said Dr Head. "You can catch it by prolonged skin-to-skin contact, or via clothes, furniture or bedding that an infected person may have used previously." Don't miss the latest news from around Scotland and beyond - Sign up to our daily newsletter here.Ex-Colorado footballer Bloom dedicates time to fulfilling wishes for older adults

Stock Music Market to Grow by USD 650.4 Million from 2023-2028, Report on AI Redefining Market Landscape - Technavio

Ex-CNN anchor Don Lemon was very upset with Time magazine naming President-elect Donald Trump as the magazine’s annual Person of the Year , asking if the magazine took into consideration its women readers. Lemon made his comments on his show, The Don Lemon Show, questioning if magazines “even matter anymore” following its award to Trump. He added that the magazine should have given the award to “any person” who “stands for democracy,” adding that winning the presidential election does not automatically make someone worthy of Time’s annual title. “Time magazine, what are you doing?” Lemon asked. “Let me ask you, Time magazine: what do you say to the women who, I guess, still read Time magazine? Or the women who are — don’t they do a whole Time 100 thing or something, which ... what about the women who are on that list? What about them? I’m sure some of them have dealt with issues that women have to deal with like discrimination in workplace, SA, all kinds of things.” Lemon added that the magazine granted its title to someone who attempted to “overturn a free and fair election” and that “a convicted felon” was on the magazine’s cover. He then joked that “maybe we’re being scammed” about Trump winning the title. About who could have won the title instead, Lemon pitched the idea of naming Hunter Biden as Person of the Year since “Hunter got out of a lot of stuff, too.” CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER Trump's win as Time’s Person of the Year marks the second time he has won the title, the first being in 2016. Other nominees for this year's award included Vice President Kamala Harris, X owner Elon Musk, podcast host Joe Rogan, Meta CEO Mark Zuckerberg, and Princess of Wales Kate Middleton. Donald Trump is TIME's Person of the Year https://t.co/IjP5W2otV5 pic.twitter.com/CVHX9o0DB3 — TIME (@TIME) Thursday, Trump also rang the opening bell of the New York Stock Exchange , marking the first time he had the honors in his hometown of New York City. Trump’s Person of the Year magazine cover was projected on the NYSE floor along with American flags, as “USA” chants proceeding Trump’s bell ringing were heard.

European Cup News

European Cup video analysis

  • cat slots game
  • jili online
  • jili1111
  • milyon88 apk latest version
  • okebet gaming app
  • jili1111